sameAs
The Development of Human Immunologic Assays Specific to Folate Receptor AntigenA Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate CancerChemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian CancerA Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian CancerInfluence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian CancerMasitinib in Ovarian CancerTrial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)Phase 2 Trial of Maintenance Vigil for High Risk Stage IIIb-IV Ovarian CancerTrial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian CancerTo Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid TumorsOpen Label Immunotherapy Trial for Ovarian CancerA Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic CancersPilot Study of Durvalumab and Vigil in Advanced Women's CancersDurvalumab, Tremelimumab + Radiotherapy in Gynecologic CancerNeo-adjuvant Pembrolizumab in Primary Stage IV Ovarian CancerNivolumab and Ipilimumab in Treating Patients With Rare TumorsAutologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal AdenocarcinomaCellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal CancerThe Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer PatientsEfficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer PatientsScreening and Identification of Ovarian CancersTrial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer PatientsCharacterization of Ovarian Cancer Stem CellThe Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian CancerCT Antigen TCR-redirected T Cells for Ovarian Cancer.A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic CancerPembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid TumorsNivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerPembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerFirst-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid TumorsGL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian CancerPegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCombination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian CancerPD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerGenetically Modified T Cells Against Ovarian CancerRibociclib + PDR001 in Breast Cancer and Ovarian CancerAnti—PD-L1 and SAbR for Ovarian CancerEngineered Immune Effectors Against Ovarian CancerIntervention of Ovarian Cancer With Antigen-specific Engineered Immune EffectorsStudy of 6b11-OCIK Injection Treatment in Patients With Drug-resistant and Recurrence Epithelial Ovarian Cancer
P1050
Tensor GSVD of patient- and platform-matched tumor and normal DNA copy-number profiles uncovers chromosome arm-wide patterns of tumor-exclusive platform-consistent alterations encoding for cell transformation and predicting ovarian cancer survivalIncreased expression of PITX2 transcription factor contributes to ovarian cancer progressionThe role of protein elongation factor eEF1A2 in ovarian cancerCD133 antigen expression in ovarian cancerNovel genetic variants in miR-191 gene and familial ovarian cancerRole of gonadotropin-releasing hormone (GnRH) in ovarian cancerThe BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancersAnimal models of ovarian cancerOvarian surface epithelium: family history and early events in ovarian cancerThe role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancerRole of BRCA gene dysfunction in breast and ovarian cancer predisposition.Early events in ovarian oncogenesisMitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epitheliumEstrogen, progesterone and epithelial ovarian cancerFinding all BRCA pathogenic mutation carriers: best practice modelsNew challenges for BRCA testing: a view from the diagnostic laboratoryAscites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancerClear cell carcinoma of the ovary: molecular insights and future therapeutic perspectivesAn overview of long non-coding RNAs in ovarian cancersGenetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapyEndocrine disrupting chemicals (EDCs) and female cancer: Informing the patientsHigh Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate CancerDepression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence ratesGoitre ovarien bénin: à propos d’un cas et revue de la littératureAppendiceal mixed adenoneuroendocrine carcinomas, a rare entity that can present as a Krukenberg tumor: case report and review of the literatureThe Potential Role of the Proteases Cathepsin D and Cathepsin L in the Progression and Metastasis of Epithelial Ovarian CancerMaintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-AnalysisMitotically active cellular fibroma of the ovary: a case report and literature reviewLesser-Known Molecules in Ovarian CarcinogenesisPrognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-AnalysisThe Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive LifePrognostic Value of FOXM1 in Patients with Malignant Solid Tumor: A Meta-Analysis and System ReviewOvarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reductionMicroRNAs in ovarian function and disordersImpact of statins on risk and survival of ovarian cancerRole of aggressive surgical cytoreduction in advanced ovarian cancerOvarian serous carcinoma: recent concepts on its origin and carcinogenesisRole of mesenchymal cells in the natural history of ovarian cancer: a reviewOccupational cancer in Britain. Female cancers: breast, cervix and ovaryTargeted anti-vascular therapies for ovarian cancer: current evidence
P921
Q58406139-29007E5A-7B74-4FC4-96E0-FF3977020D9CQ58407485-FDD1667D-12B3-459B-8CD4-2EFD26CC2F4DQ58407518-3814E4FA-6ECC-4BBC-93EB-C389968DF63BQ58407546-7E9386DA-B69D-42CF-B0E1-86241E2DF78DQ58407556-B74BFFDC-21EF-4C6A-AE1E-7C53BBD03F66Q58407609-B84B2AEE-0A93-40E7-AB8D-5EE96AB4925FQ58407623-4AC417CD-D5BB-4E62-B4ED-70805205E0EAQ58407640-17CFBA21-2162-4A98-929F-159D7FF484DFQ58407642-68B45971-F99E-4858-B5F7-F6C937561980Q58407667-EEF62A69-7E5B-426D-87CC-8DE40E8009F0Q58407698-C3C060EE-3533-43E9-A999-97082E5DEF78Q58407701-42EB4177-E957-47FD-860E-E27051699BC1Q58407702-C604275C-9ED5-4079-9480-71E7A5CFB426Q58407722-ACC749FC-392A-4AC0-AB4E-41B9C02C51AFQ58407764-5A4F96F6-4C15-4122-8713-AD2B1FBC1EA2Q58407779-46A1B13B-028E-4141-B039-0A4B8993B0F9Q58407852-5D0EAD21-68B1-453A-9684-606B98865098Q58844289-2D62D45F-4345-48CA-8634-EF6211474E90Q58844331-AEC50CE8-6D6B-4A07-9615-008362E4D4A4Q58844406-1C524042-5187-4979-B61D-BA48FE4DF2A8Q58844551-FD0482F2-086A-4B39-AF85-5D940122DE2FQ58844748-D58CAC66-24A9-496E-B6AC-C0EC17B31EDCQ58844765-12F71066-CDCE-43EA-A1A1-377CCE9BFA61Q58844825-966878DA-AE5C-48BA-902D-835BA22335AFQ58844832-C5FC5A9C-4766-4FB3-B46C-CB9A8C157A1CQ58844962-8C07F9D5-D86E-4C0E-8A47-DE3A131E248FQ58845114-F6B24408-436D-42B5-84DE-BF12F5D7310BQ58845348-93DA6AF7-9628-4B09-8572-92582E523DCCQ58845373-DCE61CAF-7AED-40C7-ADE4-A31FB17AE320Q58845525-1DFA2681-3987-44F0-986F-3BE5F6B6BB1BQ58845558-284013E0-4DFE-4FAB-89BA-E40AE688CAFAQ58845627-D66E4B82-03C6-44AE-A49F-3A313FE1213BQ58845776-93F6E83A-AF1D-4374-93FD-B381CA1AE823Q58845904-C183C9B6-30B7-4F78-B261-8D804152AA68Q58846356-CC7C5711-9D1F-4613-B971-A9D5A684CD20Q58846529-F1D0D5B0-5E11-487B-A5F8-4498DE0D8910Q58846548-FB2D385E-AD68-4374-B540-CB25BAEE917AQ58846708-54789C03-F645-4AB9-BE48-20EA1E460C64Q58846752-4C10E1FB-0292-4C57-915C-FBE7385F75ABQ58846903-D32FD42D-E3C8-4B86-9832-79DF9943B889
P1050
Q147362-a05e7db9-421a-b660-c46a-de014aa9890eQ172341-f95fd150-4782-3bba-0885-7ac93201b21bQ1808930-76cd9cfe-47ef-a8bb-de72-8097b6dd1023Q18553671-4C235B21-78EE-4EE9-BFF7-A755CA705ECDQ18555019-08254D87-E85F-475D-B9CC-BAC977DE5EF2Q18556529-6B42039B-5799-4BE1-B8E9-953FE166F107Q55789513-fb5c4774-4a0b-5374-afed-7e26abc6d3b8Q7645976-5a8fb1f1-4fa3-b420-6679-6cc056b4363e
P279
Q21090556-696683A2-B60F-49BE-9D21-DBA8053B6500Q21090912-B455663C-4ECD-43E5-9A82-9ACDA328CD2BQ21093260-A510ABAC-89AD-41B6-A63F-0B5F51D96D7AQ21093306-980531F3-EEC6-441A-8A8F-63A5E721EFB0Q21093320-81BB89C5-8CE1-48DC-A055-6E80CADA759EQ21245571-E4F67C1C-95ED-4416-BA13-4194C49D9563Q21260410-987B1872-FDF0-4B04-B4B5-F54597BBD7D5Q24791470-8708E9F3-8718-4B99-8F52-37ECD19D62C2Q24791495-809A4A3B-6FB1-484A-AA0F-F8A533810350Q24791520-2EED15A3-83BF-4761-AAFB-0EA02CABDF7BQ24800677-E09C98A2-57B9-4F8A-82A6-F29B9FAC6B67Q24805567-3ACE92A6-8742-461B-828F-01F2549D5977Q24805605-0C21A4D2-3BDE-4BDC-9367-8774164955A2Q24805637-C24D81E1-2DD6-4E48-8129-398EEE817891Q26741854-DCA1BD15-29CF-4F32-B0CD-060F100A5208Q26741855-392ADACA-6175-4650-A107-8C6A6824D9E8Q26746203-98D34F74-50D3-4134-862C-EC4E2F08BE81Q26749280-F5A62889-D963-4FB1-8F60-95371B57B3CFQ26753467-FB97EA2D-9746-4563-B4B9-16E7539F0434Q26769604-E3B2D4B7-EB73-466D-9EA6-53F75F01896EQ26772899-BFB12BB2-2F81-406B-B6F1-C270AD0019A1Q26774902-D690EC03-FA8A-488F-8E01-89E5FAAD6872Q26775898-4F49F277-86AE-414D-86C6-1A9B74D19F4FQ26776218-B1E0350E-1380-4E6B-BC8A-B72D1692DF39Q26776430-A0AC592B-C531-4302-BDE1-E42F199BE178Q26776510-BAC5641F-71DF-4AD7-BF71-6BD0B270B043Q26781561-DD3532FB-8FE0-4CB4-BE19-CECA636E88A4Q26781961-062A6C9D-F859-49C0-9E57-E25CCFD51DACQ26784533-A5A6F19A-C0DC-4B2E-BC7D-593487EE910DQ26785421-FF4CF99C-BE0C-464C-9B60-6AA883AE7128Q26785614-F26535FD-BC5F-4684-A50C-DCCC08256677Q26785676-ADA8815D-F7A5-4AEF-8CB4-F4E8AEBE144AQ26786610-70CD20AE-E653-404F-B0DE-C68A74CA3ED0Q26800404-2C42805D-EA13-4064-B041-46AA2147F068Q26801352-09314C93-F188-4DFD-96D1-B6C28F8A7A5BQ26801358-D5B1A114-8E30-4C2B-8EDF-D83728B6F837Q26822545-95C1F529-5FC8-46C6-9A55-CDBCD9951A55Q26823555-D2FE2BA7-7CE3-451A-A057-98AFB121A28DQ26828550-32A8B57F-DE66-4BD4-9F3F-8E286DFF1757Q26830287-0D53168C-95B9-4AA7-9C21-5BF7E455AA9A
P921
description
benign, borderline, or malignant neoplasm involving the ovary
@en
Ձվարանի հյուսվածքի բարորակ, սահմանային կամ չարորակ փոփոխություններ
@hy
name
Eierstock Tumor
@de
Tumor ovarii
@la
Tumori jajnika
@sr
eggstokksvulst
@nn
ovarian neoplasm
@en
tumeur de l'ovaire
@fr
tumor do ovário
@pt
tumor ovàric
@ca
tumor ovárico
@es
Ձվարանի նեոպլազիա
@hy
type
label
Eierstock Tumor
@de
Tumor ovarii
@la
Tumori jajnika
@sr
eggstokksvulst
@nn
ovarian neoplasm
@en
tumeur de l'ovaire
@fr
tumor do ovário
@pt
tumor ovàric
@ca
tumor ovárico
@es
Ձվարանի նեոպլազիա
@hy
altLabel
Neoplasm of Ovary
@en
Neoplasm of the Ovary
@en
Ovarian Neoplasm
@en
Ovarian Tumor
@en
Ovarian Tumors
@en
Tumor of Ovary
@en
Tumor of the Ovary
@en
ovarian neoplasms
@en
ovarian tumor
@en
ovarietumor
@nn
prefLabel
Eierstock Tumor
@de
Tumor ovarii
@la
Tumori jajnika
@sr
eggstokksvulst
@nn
ovarian neoplasm
@en
tumeur de l'ovaire
@fr
tumor do ovário
@pt
tumor ovàric
@ca
tumor ovárico
@es
Ձվարանի նեոպլազիա
@hy
P279
P672
P486
P6366
P1692
P1748
P1995
P2892
P31
P486
P5270
MONDO:0021068
P6366
2780084626
P672
C04.588.322.455
C13.351.500.056.630.705
C13.351.937.418.685
C19.344.410
C19.391.630.705